NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Slight increase in greenhouse gasses in 2021 In 2021, greenhouse gas emissions were 1.8% higher than the year before. This marked the first time emissions had gone up since 2016. In 2020, emissions declined by 8.8%. The 2021 increase is largely attributable to CO2 and to the cold winter.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Air quality in the Netherlands in 2021 almost the same as in 2020 In 2021, the Netherlands once again met the European limit values for nitrogen dioxide emitted at ground-level by road traffic. This was also the case for particulate matter along the roads, with the exception of a small stretch of road near Velsen.
Higher alert level for Ebola There is an Ebola outbreak in several regions of Uganda that are also frequented by tourists. RIVM therefore asks medical professionals to be alert to symptoms that could indicate Ebola among people who have travelled to Uganda, and to request diagnostics to rule out or confirm Ebola.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.